Jefferies (NYSE:JEF) analyst Maury Raycroft maintained a Buy rating on Valneva on Friday, setting a price target of $36, which is approximately 32.06% above the present share price of $27.26.
Raycroft expects Valneva to post earnings per share (EPS) of $0.00 for the third quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Valneva, with an average price target of $26.55.
The analysts price targets range from a high of $36 to a low of $17.11.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $23.22 million and a net profit of -$31.14 million. The company's market cap is $1.36 billion.
According to TipRanks.com, Jefferies analyst Maury Raycroft is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.2% and a 41.83% success rate.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.